A20 ZF7 domain base-edited CAR-T cells

A20 ZF7 domain base-edited CAR-T cells are an experimental adoptive cellular therapy designed to improve the persistence and cytotoxic function of T cells in the tumor microenvironment. Using base editing technology, a precise missense mutation is introduced into the zinc finger 7 (ZF7) domain of the A20 protein (encoded by the TNFAIP3 gene), which normally acts as a negative regulator of T cell activation. Unlike full gene knockout, this targeted domain ablation preserves other essential regulatory functions of the multifunctional A20 protein. Preclinical studies in xenograft models of hematologic and solid tumors have demonstrated that these engineered CAR-T cells exhibit superior tumor control, increased cytokine production, and reduced expression of inhibitory receptors compared to standard CAR-T cells.

Other names

ZF7-base edited CAR-T cellsZF-7-base edited CAR-T cellsZF 7-base edited CAR-T cellsA20 ZF7-edited CAR-T cellsA-20 ZF7-edited CAR-T cellsA 20 ZF7-edited CAR-T cellsA20-mutant CAR-T cellsA-20-mutant CAR-T cellsA 20-mutant CAR-T cells